Basilea Pharmaceutica AG

As of June 30, 2026, Basilea Pharmaceutica AG carries a market capitalization of 714.13M, placing it among publicly traded companies globally. Its enterprise value stands at 617.04M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Basilea Pharmaceutica AG's next confirmed earnings release is scheduled for February 16, 2027.

As of June 30, 2026, Basilea Pharmaceutica AG has 12.38M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Basilea Pharmaceutica AG maintains a current ratio of 6.60, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Basilea Pharmaceutica AG's stock has gained approximately 42.77% over the past 52 weeks. The 50-day moving average sits at 69.70, while the 200-day moving average is 60.70.

As of June 30, 2026, Basilea Pharmaceutica AG holds 187.51M in cash and equivalents against 90.41M in total debt, resulting in a net debt position of -110.96M. Total book value stands at 175.91M, with working capital of 251.69M providing operational flexibility.

Basilea Pharmaceutica AG's most recent stock split took place on March 13, 2007.